GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » Notes Receivable

Fresh2 Group (Fresh2 Group) Notes Receivable : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group Notes Receivable?

Fresh2 Group's Notes Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.


Fresh2 Group Notes Receivable Historical Data

The historical data trend for Fresh2 Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group Notes Receivable Chart

Fresh2 Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Notes Receivable
Get a 7-Day Free Trial - - - - -

Fresh2 Group Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fresh2 Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Fresh2 Group Notes Receivable Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh2 Group (Fresh2 Group) Business Description

Traded in Other Exchanges
Address
650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.